Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

Chronic lymphocytic leukemia (CLL) is associated with perturbed immune function and increased risk for second primary malignancies (SPM). Ibrutinib and acalabrutinib (BTKi) are effective therapies for CLL resulting in partial restoration of immune function. The incidence of and risk factors for SPM...

Descripción completa

Detalles Bibliográficos
Autores principales: Bond, David A, Huang, Ying, Fisher, James L, Ruppert, Amy S, Owen, Dwight H, Bertino, Erin M, Rogers, Kerry A, Bhat, Seema A, Grever, Michael R, Jaglowski, Samantha M, Maddocks, Kami J, Byrd, John C, Woyach, Jennifer A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688551/
https://www.ncbi.nlm.nih.gov/pubmed/32704159
http://dx.doi.org/10.1038/s41375-020-0987-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688551/
https://www.ncbi.nlm.nih.gov/pubmed/32704159
http://dx.doi.org/10.1038/s41375-020-0987-6

Ejemplares similares